

# Jesper BÃ¸je Andersen

List of Publications by Year  
in descending order

Source: <https://exaly.com/author-pdf/8023989/publications.pdf>

Version: 2024-02-01

106  
papers

8,952  
citations

53751

45  
h-index

43868

91  
g-index

108  
all docs

108  
docs citations

108  
times ranked

11906  
citing authors

#	ARTICLE	IF	CITATIONS
1	The proteaseâ€inhibitor SerpinB3 as a critical modulator of the stemâ€like subset in human cholangiocarcinoma. Liver International, 2022, 42, 233-248.	1.9	15
2	Mucosalâ€associated invariant Tâ€cell tumor infiltration predicts longâ€term survival in cholangiocarcinoma. Hepatology, 2022, 75, 1154-1168.	3.6	14
3	Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities. Theranostics, 2022, 12, 260-276.	4.6	16
4	Cholangiocarcinoma progression depends on the uptake and metabolism of extracellular lipids. Hepatology, 2022, 76, 1617-1633.	3.6	15
5	miRâ€579â€3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3â€Kinaseâ€Protein Kinase B Pathway in Chronically Inflamed Liver. Hepatology Communications, 2022, 6, 1467-1481.	2.0	8
6	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology, 2022, 76, 1109-1121.	1.8	119
7	Molecular therapeutic targets for cholangiocarcinoma: Present challenges and future possibilities. Advances in Cancer Research, 2022, , .	1.9	1
8	Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. Journal of Hepatology, 2022, 77, 177-190.	1.8	11
9	Lipid alterations in chronic liver disease and liver cancer. JHEP Reports, 2022, 4, 100479.	2.6	69
10	Mutational signatures and processes in hepatobiliary cancers. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 367-382.	8.2	2
11	Stromal yinâ€yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma. Hepatology, 2022, , .	3.6	0
12	Involvement of Epigenomic Factors in Bile Duct Cancer. Seminars in Liver Disease, 2022, 42, 202-211.	1.8	0
13	Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer. Journal of Hepatology, 2022, 77, 1047-1058.	1.8	7
14	Molecular Targets in Cholangiocarcinoma. Hepatology, 2021, 73, 62-74.	3.6	26
15	Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes. Journal of Hepatology, 2021, 74, 1132-1144.	1.8	30
16	TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms. Gut, 2021, 70, 1345-1361.	6.1	59
17	E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment. Cancer Research, 2021, 81, 2874-2887.	0.4	27
18	Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. Journal of Hepatology, 2021, 74, 1373-1385.	1.8	60

#	ARTICLE	IF	CITATIONS
19	Extracellular Signalâ€Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells. Hepatology, 2021, 74, 2007-2020.	3.6	12
20	Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesis. JCI Insight, 2021, 6, .	2.3	9
21	Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma. BMC Cancer, 2021, 21, 1079.	1.1	14
22	The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. EBioMedicine, 2021, 73, 103661.	2.7	31
23	Structural aberrations are associated with poor survival in patients with clonal cytopenia of undetermined significance. Haematologica, 2021, 106, 1762-1766.	1.7	6
24	Identification of a Panâ€Gammaâ€Secretase Inhibitor Response Signature for Notchâ€Driven Cholangiocarcinoma. Hepatology, 2020, 71, 196-213.	3.6	29
25	Dual-initiation promoters with intertwined canonical and TCT/TOP transcription start sites diversify transcript processing. Nature Communications, 2020, 11, 168.	5.8	37
26	Determination of primary microRNA processing in clinical samples by targeted pri-miR-sequencing. Rna, 2020, 26, 1726-1730.	1.6	5
27	Intrahepatic cholangiocarcinoma: A single-cell resolution unraveling the complexity of the tumor microenvironment. Journal of Hepatology, 2020, 73, 1007-1009.	1.8	9
28	Ancestrally Duplicated Conserved Noncoding Element Suggests Dual Regulatory Roles of HOTAIR in cis and trans. IScience, 2020, 23, 101008.	1.9	9
29	Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers. Clinical Cancer Research, 2020, 26, 5655-5667.	3.2	21
30	Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. Cells, 2020, 9, 721.	1.8	63
31	Therapeutic Rationale to Target Highly Expressed Aurora kinase A Conferring Poor Prognosis in Cholangiocarcinoma. Journal of Cancer, 2020, 11, 2241-2251.	1.2	1
32	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588.	8.2	1,155
33	Epigenome Remodeling in Cholangiocarcinoma. Trends in Cancer, 2019, 5, 335-350.	3.8	36
34	The protein kinase CK2 contributes to the malignant phenotype of cholangiocarcinoma cells. Oncogenesis, 2019, 8, 61.	2.1	27
35	Therapeutic Potential of Pharmacoepigenetics in Cholangiocarcinoma. , 2019, , 551-562.		0
36	Cholangiocarcinoma: Stateâ€ofâ€theâ€art knowledge and challenges. Liver International, 2019, 39, 5-6.	1.9	6

#	ARTICLE	IF	CITATIONS
37	Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?. Liver International, 2019, 39, 32-42.	1.9	21
38	Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy. Hepatology, 2019, 70, 1246-1261.	3.6	41
39	A morphogenetic EphB/EphrinB code controls hepatopancreatic duct formation. Nature Communications, 2019, 10, 5220.	5.8	14
40	Metabolic rearrangements in primary liver cancers: cause and consequences. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 748-766.	8.2	144
41	Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib. British Journal of Pharmacology, 2019, 176, 787-800.	2.7	39
42	Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification. International Journal of Cancer, 2019, 144, 2782-2794.	2.3	19
43	Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma. Trends in Cancer, 2018, 4, 239-255.	3.8	92
44	Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology, 2018, 68, 949-963.	3.6	106
45	Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma. Liver International, 2018, 38, 113-124.	1.9	33
46	Epigenome dysregulation in cholangiocarcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1423-1434.	1.8	31
47	Reply. Gastroenterology, 2018, 154, 260-261.	0.6	0
48	MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology, 2018, 154, 1066-1079.e5.	0.6	94
49	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- $\beta$ 2 Superfamily. Cell Systems, 2018, 7, 422-437.e7.	2.9	134
50	Single cell profiling reveals window for immunotherapy in liver cancers. Hepatobiliary Surgery and Nutrition, 2018, 7, 48-51.	0.7	3
51	RNAi screening of subtracted transcriptomes reveals tumor suppression by taurine-activated GABAA receptors involved in volume regulation. PLoS ONE, 2018, 13, e0196979.	1.1	1
52	An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nature Communications, 2017, 8, 14294.	5.8	119
53	SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma. Journal of Hepatology, 2017, 67, 72-83.	1.8	81
54	Advances in the molecular characterization of liver tumors. , 2017, , 133-138.e2.		0

#	ARTICLE	IF	CITATIONS
55	Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets. Expert Review of Gastroenterology and Hepatology, 2017, 11, 349-356.	1.4	16
56	Association of Aflatoxin and Gallbladder Cancer. Gastroenterology, 2017, 153, 488-494.e1.	0.6	49
57	High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy. Molecular Carcinogenesis, 2017, 56, 2146-2157.	1.3	17
58	Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma. Cancer Cell, 2017, 32, 57-70.e3.	7.7	324
59	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports, 2017, 18, 2780-2794.	2.9	416
60	Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells. Scientific Reports, 2017, 7, 17667.	1.6	60
61	Genetic Optimization of Liver Cancer Therapy: A Patient-Derived Primary Cancer Cell-Based Model. Gastroenterology, 2017, 152, 19-21.	0.6	4
62	Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. Journal of Hepatology, 2017, 66, 102-115.	1.8	130
63	Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas. Oncotarget, 2017, 8, 48688-48700.	0.8	15
64	Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. Journal of Gastrointestinal Oncology, 2016, 7, 819-827.	0.6	17
65	Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype. Hepatology, 2016, 63, 1888-1899.	3.6	40
66	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Reviews Gastroenterology and Hepatology, 2016, 13, 261-280.	8.2	964
67	Transcriptional, post-transcriptional and chromatin-associated regulation of pri-miRNAs, pre-miRNAs and moRNAs. Nucleic Acids Research, 2016, 44, 3070-3081.	6.5	38
68	Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma. Digestive Diseases, 2016, 34, 440-451.	0.8	20
69	A Gene Expression Signature Associated with Overall Survival in Patients with Hepatocellular Carcinoma Suggests a New Treatment Strategy. Molecular Pharmacology, 2016, 89, 263-272.	1.0	21
70	Heterogeneity Among Liver Cancer—A Hurdle to Optimizing Therapy. Gastroenterology, 2016, 150, 818-821.	0.6	7
71	Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: Molecular networks and biological concepts. Journal of Hepatology, 2015, 62, 198-207.	1.8	66
72	Fibrolamellar Hepatocellular Carcinoma: A Rare but Distinct Type of Liver Cancer. Gastroenterology, 2015, 148, 707-710.	0.6	11

#	ARTICLE	IF	CITATIONS
73	Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. Hepatic Oncology, 2015, 2, 79-93.	4.2	16
74	Curcumin effectively inhibits oncogenic NF- $\kappa$ B signaling and restrains stemness features in liver cancer. Journal of Hepatology, 2015, 63, 661-669.	1.8	237
75	Functional and genetic deconstruction of the cellular origin in liver cancer. Nature Reviews Cancer, 2015, 15, 653-667.	12.8	249
76	Molecular pathogenesis of intrahepatic cholangiocarcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 101-113.	1.4	51
77	A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. Hepatic Oncology, 2014, 1, 143-157.	4.2	16
78	Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology, 2014, 59, 911-923.	3.6	382
79	Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. Journal of Hepatology, 2014, 60, 346-353.	1.8	85
80	Epigenetic reprogramming modulates malignant properties of human liver cancer. Hepatology, 2014, 59, 2251-2262.	3.6	75
81	p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer. Cell, 2014, 158, 579-592.	13.5	176
82	MYC Activates Stem-like Cell Potential in Hepatocarcinoma by a p53-Dependent Mechanism. Cancer Research, 2014, 74, 5903-5913.	0.4	71
83	Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2. Cancer Research, 2014, 74, 4752-4761.	0.4	74
84	Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends. Journal of Hepatology, 2014, 60, 855-865.	1.8	262
85	Molecular constituents of the extracellular matrix in rat liver mounting a hepatic progenitor cell response for tissue repair. Fibrogenesis and Tissue Repair, 2013, 6, 21.	3.4	17
86	Genomic Decoding of Intrahepatic Cholangiocarcinoma Reveals Therapeutic Opportunities. Gastroenterology, 2013, 144, 687-690.	0.6	18
87	Modeling Pathogenesis of Primary Liver Cancer in Lineage-Specific Mouse Cell Types. Gastroenterology, 2013, 145, 221-231.	0.6	153
88	Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling. Genes and Development, 2013, 27, 1706-1717.	2.7	90
89	Genetic profiling of intrahepatic cholangiocarcinoma. Current Opinion in Gastroenterology, 2012, 28, 266-272.	1.0	82
90	Next-Generation Sequencing: Application in Liver Cancer—Past, Present and Future?. Biology, 2012, 1, 383-394.	1.3	16

#	ARTICLE	IF	CITATIONS
91	Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors. <i>Gastroenterology</i> , 2012, 142, 1021-1031.e15.	0.6	443
92	Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. <i>Hepatology</i> , 2012, 56, 1792-1803.	3.6	203
93	mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma. <i>Science Translational Medicine</i> , 2012, 4, 139ra84.	5.8	88
94	Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. <i>Hepatology</i> , 2011, 54, 1031-1042.	3.6	72
95	Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. <i>Journal of Experimental Medicine</i> , 2011, 208, 1963-1976.	4.2	183
96	Coactivation of AKT and $\beta$ -Catenin in Mice Rapidly Induces Formation of Lipogenic Liver Tumors. <i>Cancer Research</i> , 2011, 71, 2718-2727.	0.4	73
97	Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. <i>Journal of Cell Biology</i> , 2011, 194, i11-i11.	2.3	0
98	Progenitor-derived hepatocellular carcinoma model in the rat. <i>Hepatology</i> , 2010, 51, 1401-1409.	3.6	118
99	An Integrated Genomic and Epigenomic Approach Predicts Therapeutic Response to Zebularine in Human Liver Cancer. <i>Science Translational Medicine</i> , 2010, 2, 54ra77.	5.8	92
100	Definition of Ubiquitination Modulator COP1 as a Novel Therapeutic Target in Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2010, 70, 8264-8269.	0.4	65
101	Loss of c-Met Disrupts Gene Expression Program Required for G2/M Progression during Liver Regeneration in Mice. <i>PLoS ONE</i> , 2010, 5, e12739.	1.1	66
102	Ribosomal protein mRNAs are primary targets of regulation in RNase-L-induced senescence. <i>RNA Biology</i> , 2009, 6, 305-315.	1.5	56
103	UBE1L causes lung cancer growth suppression by targeting cyclin D1. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3780-3788.	1.9	72
104	Post-transcriptional Regulation of RNase-L Expression Is Mediated by the 3'-Untranslated Region of Its mRNA. <i>Journal of Biological Chemistry</i> , 2007, 282, 7950-7960.	1.6	39
105	Interaction between the 2'-5' oligoadenylate synthetase-like protein p59 OASL and the transcriptional repressor methyl CpG-binding protein 1. <i>FEBS Journal</i> , 2004, 271, 628-636.	0.2	25
106	The Altered Serum Lipidome and its Diagnostic Potential for Non-Alcoholic Fatty Liver (NAFL)-Associated Hepatocellular Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1